natgillin/translations-raw huggingface dataset:
Blandt disse patienter opnåede 37 %, der fik vedolizumab hver 8. uge, 35 %, der fik vedolizumab hver 4. uge, og 5 %, der fik placebo, klinisk remission i uge 52.
Among these patients, 37% receiving vedolizumab every eight weeks, 35% receiving vedolizumab every four weeks, and 5% receiving placebo achieved clinical remission at Week 52.
Blandt disse patienter var den positive prognostiske værdi af SVR12 for SVR24 99,8 %.
Among these subjects, the positive predictive value of SVR12 on SVR24 was 99.8%.
Blandt disse patienter var der opnået klinisk remission hos 25 % af patienterne i uge 28 og uge 52.
In these patients, clinical remission was achieved in 25% of patients at Week 28 and Week 52.
Blandt disse rapporterede alle karlæsioner i albueregionen men også neurologiske symptomer (1 tilfælde), knogle- og muskelsmerter (2 tilfælde) og hudstriber (2 tilfælde).
Of them, all reported vascular elbow lesions, but also neurologic symptoms (1 case), bone and muscle pain (2 cases), and skin striae (2 cases).
Blandt disse tilstande er BK- virus-associeret nefropati og JC-virus-associeret progressiv multifokal leukoencefalopati (PML).
Among these conditions are BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML).
Blandt disse tilstande er BK-virus associeret nefropati og JC-virus associeret progressiv multifokal leukoencefalopati (PML).
Among these conditions are BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML).
Blandt disse tilstande er BK-virus- associeret nefropati og JC-virus-associeret progressiv multifokal leukoencefalopati (PML).
Among these conditions are BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML).
Blandt disse var en forøget forekomst af fæokromocytomer i binyrerne hos hanrotter sammenlignet med kontrollen på alle dosisniveauer ( 3 mg/kg/dag) og hos hunrotter, som modtog 10 mg/kg/dag og derover.
Among them, the incidence of adrenal phaeochromocytomas was increased relative to control in males at all dose levels ( 3 mg/kg/day) and in females receiving 10 mg/kg/day and above.
Blandt entecavir-behandlede patienter gik der i gennemsnit 4 - 5 uger inden eksacerbationerne indtrådte.
Among entecavir-treated patients on-treatment exacerbations had a median time of onset of 4-5 weeks.
Blandt forsøgspersonerne med observerede data ved uge 16 i de fire fase 3 kliniske forsøg havde 50,8 % af de randomiserede til at modtage naltrexon/bupropion mistet ≥5 % af baseline kropsvægt sammenlignet med 19,3 % af placebo-behandlede forsøgspersoner (uge 16 respondenter).
Of the subjects with observed data at Week 16 in the four Phase 3 clinical trials, 50.8% of those randomized to receive naltrexone / bupropion had lost ≥5% of their baseline body weight, compared to 19.3% of placebo-treated subjects (Week 16 Responders).
Blandt genotype 1a-inficerede forsøgspersoner var medianalderen 54 år (19 til 76); 71% var mænd; 71% var kaukasere; 22% var negroide eller afroamerikanere; 9% var latinamerikanere; 74% var behandlingsnaive; 26% var behandlingserfarne; gennemsnitligt BMI var 27 kg/m2; 75% havde HCV- RNA over 800.000 IE/ml ved baseline; 23% havde cirrose; 72% havde ikke-C/C IL28B-alleler (CT- eller TT-genotyper); 30% havde HCV/hiv 1-co-infektion.
Among genotype 1a-infected subjects, the median age was 54 years (range: 19 to 76); 71 % were male; 71 % were White; 22 % were Black or African American; 9% were Hispanic or Latino; 74% were treatment-naïve subjects; 26% were treatment-experienced subjects; mean body mass index was 27 kg/m2; 75 % had baseline HCV RNA levels greater than 800,000 IU/mL; 23 % had cirrhosis; 72% had non-C/C IL28B alleles (CT or TT); 30 % had HCV/HIV-1 co-infection.
Blandt genotype 1b-inficerede forsøgspersoner var NS5A-resistens- associerede substitutioner persistente med detekterbare niveauer hos 100% (7/7) af forsøgspersonerne ved opfølgningsuge 12 og hos 100% (3/3) af forsøgspersonerne med data fra opfølgningsuge 24.
Among genotype 1b- infected subjects, NS5A resistance-associated substitutions persisted at detectable levels in 100% (7/7) of subjects at follow-up week 12 and in 100% (3/3) of subjects with follow-up week 24 data.
Blandt HBeAg-positive patienter var der i uge 104 tiltagende forskel i terapeutisk respons (63 % vs 48 %; p<0,0001) og vigtigste sekundære endepunkter (middel log10 HBV-DNA reduktion; -5,74 vs - 4,42: p<0,0001, ikke målbart HBV-DNA: 56 % vs 39 %: p<0,0001 og ALAT normalisering på 70 % vs 62 %) mellem henholdsvis telbuvidin og lamivudin.
Among HBeAg-positive patients, therapeutic response (63% vs 48%; p < 0.0001) and key secondary endpoints (mean log10 HBV DNA reduction: -5.74 vs -4.42; p < 0.0001, HBV DNA undetectability: 56% vs 39%; p < 0.0001 and ALT normalisation of 70% vs 62%) demonstrated a widening difference at week 104 between telbivudine and lamivudine, respectively.
Blandt hiv-inficerede patienter med svær immuninsufficiens kan der ved påbegyndelse af antiretroviral kombinationsbehandling (CART) opstå en inflammatorisk reaktion på asymptomatiske eller residuale opportunistiske patogener, som kan forårsage alvorlige kliniske tilstande eller forværring af symptomerne.
In HIV-infected patients with severe immune deficiency at the time of institution of combination anti- retroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Blandt imatinib-intolerante patienter var den estimerede hyppighed af PFS 98% (95% KI: [95%-100%]) efter et år og 94% (95% KI: [88%-99%]) efter to år.
Among imatinib-intolerant patients, the estimated rate of PFS was 98% (95% CI: [95%-100%]) at 1 year and 94% (95% CI: [88%-99%]) at 2 years.
Blandt imatinib-resistente patienter var den estimerede hyppighed af PFS 88% (95% KI: [84%-92%]) efter et år og 75% (95% KI: [69%-81%]) efter to år.
Among imatinib-resistant patients, the estimated rate of PFS was 88% (95% CI: [84%-92%]) at 1 year and 75% (95% CI: [69%-81%]) at 2 years.
Blandt lamivudin-refraktære patienter med baseline HBV-DNA < 107 log10 kopier/ml opnåede 64% (9/14) HBV-DNA < 300 kopier/ml i Uge 48.
Among lamivudine-refractory patients with baseline HBV DNA <107 log10 copies/ml, 64% (9/14) achieved HBV DNA <300 copies/ml at Week 48.
Blandt neuropsykiatriske bivirkninger var søvnløshed den eneste rapporterede bivirkning i begge behandlingsgrupper og sås hos ≥ 5% af patienterne og med højere incidens i vareniclin-gruppen end i placebo-gruppen (9,5% vs.
Among reported neuropsychiatric adverse events, insomnia was the only event reported in either treatment group in ≥ 5% of subjects at a rate higher in the varenicline group than in placebo (9.5% vs.
Blandt overlevende moderdyr med vurderbare kuld var maternel toksicitet dog begrænset til marginale reduktioner i kropsvægt i løbet af gestationsdagene 21 til 29, og associeret udviklingstoksicitet i disse kuld var begrænset til fald i føtal kropsvægt på 7 % g en lav incidens af forsinket ossifikation af det føtale tungeben.
However, among surviving mothers with evaluable litters, maternal toxicity was limited to marginal reductions in body weight over the course of gestation days 21 to 29; and associated developmental toxicity in these litters was limited to fetal body weight decrements of 7%, and a low incidence of delayed ossification of the fetal hyoid.
Blandt patienter fra studie WV16240, som fik Pegasys-monoterapi og indgik i langtids- follow-up-studiet, var raten af vedvarende HbeAg-serokonversion 12 måneder efter afslutningen af behandlingen 48 % (73/153).
Among patients from study WV16240, who received Pegasys monotherapy and entered the long-term follow-up study, the rate of sustained HBeAg seroconversion 12 months after the end of therapy was 48% (73/153).
Blandt patienter i infliximab- gruppen 5 mg/kg, der krydsede over på grund af tab af fistula respons efter uge 22, responderede 57 % (12/21) på genbehandling med infliximab 10 mg/kg hver 8. uge.
Among patients in the infliximab 5 mg/kg group who crossed over because of loss of fistula response after week 22, 57% (12/21) responded to re-treatment with infliximab 10 mg/kg every 8 weeks.
Blandt patienter i SBR-armen, som forblev på deres baseline-program i 24 uger og dernæst skiftede til Eviplera, havde 92% (140/152) hiv 1-rna < 50 kopier/ml efter 24 uger med Eviplera, hvilket var overensstemmende med resultaterne ved uge 24 for patienter, som skiftede til Eviplera ved baseline.
Among patients in the SBR arm who maintained their baseline regimen for 24 weeks and then switched to Eviplera, 92% (140/152) of patients had HIV-1 RNA < 50 copies/mL after 24 weeks of Eviplera, consistent with the week 24 results for patients who switched to Eviplera at baseline.
Blandt patienter klassificeret som non-responderende ved uge 2, opnåede 32 % (26/81) i placebo- vedligeholdelsesgruppen og 42 % (68/163) i infliximab-gruppen klinisk respons ved uge 6.
Among patients classified as non-responders at week 2, 32% (26/81) in the placebo maintenance group and 42% (68/163) in the infliximab group achieved clinical response by week 6.
Blandt patienter med baseline Ishak fibrose-score ≥ 2, havde 25/43 (58%) ≥ 2 point fald.
For patients with baseline Ishak fibrosis score ≥ 2, 25/43 (58%) had a ≥ 2-point decrease.
Blandt patienter med evaluerbart respons var den objektive responsrate efter RECIST- kriterierne 12,2 % (95 % CI: 9,4 %; 15,5 %), baseret på en uafhængig vurdering, for eribulin-armen sammenlignet med 4,7 % (95 % CI: 2,3 %; 8,4 %) for TPC-armen.
In response evaluable patients, the objective response rate by the RECIST criteria was 12.2% (95% CI: 9.4%, 15.5%) by independent review for the eribulin arm compared to 4.7% (95% CI: 2.3%, 8.4%) for the TPC arm.
Blandt patienter med klinisk respons i uge 4 havde 48% tidligere været eksponeret for anden TNF-antagonist.
Of those in clinical response at Week 4, 48% had been previously exposed to other TNF-antagonists.
Blandt patienter med moderat til svær aktiv pædiatrisk Crohns sygdom udviklede 3,3% af de patienter, som fik adalimumab, anti-adalimumab-antistoffer.
In patients with moderately to severely active paediatric Crohn’s disease, the rate of anti-adalimumab antibody development in patients receiving adalimumab was 3.3%.
Blandt patienter med svigt af Stribild behandling, og nyopståede hiv 1 Stribild-resistenssubstitutioner, havde vira med bevaret følsomhed for alle proteasehæmmere, NNRTI’er og de fleste andre NRTI’er.
Patients who failed treatment with Stribild and who had HIV-1 with emergent Stribild resistance substitutions harboured virus that remained susceptible to all PIs, NNRTIs, and most other NRTIs.
Blandt patienter som fik imatinib 400 mg inden inklusion i studiet opnåedes MCyR hos 61% af patienterne i dasatinib-armen og 50% i imatinib-armen.
Among patients who had received imatinib 400 mg prior to study entry, MCyR was achieved in 61% of patients in the dasatinib arm and 50% in the imatinib arm.
Blandt patienter, der er co-inficeret med hcv/hiv, er der 200 celler/μl, begrænsede tilgængelige effekt- og sikkerhedsdata for patienter med CD4-tal under 200 celler/μl (N = 25).
In patients co-infected with HCV/HIV, limited efficacy and safety data (N = 25) are available in subjects with CD4 counts less than 200 cells/µl.
Blandt patienter, der er co-inficeret med hcv/hiv, er der, begrænsede tilgængelige effekt- og sikkerhedsdata for patienter med CD4-tal under 200 celler/µl (N = 25).
In patients co-infected with HCV/HIV, limited efficacy and safety data (N = 25) are available in subjects with CD4 counts less than 200 cells/µl.
Blandt patienter, der er co-inficeret med hcv/hiv, er der, begrænsede tilgængelige effekt- og sikkerhedsdata for patienter med CD4-tal under 200 celler/μl (N = 25).
In patients co-infected with HCV/HIV, limited efficacy and safety data (N = 25) are available in subjects with CD4 counts less than 200 cells/µl.
Blandt patienter, der forblev på den apremilast- behandling de blev randomiseret til ved studiestart, blev forbedringer i fysisk funktion og FACIT- fatigue opretholdt til og med uge 52.
Among patients who remained on the apremilast treatment, to which they were initially randomized at study start, improvement in physical function and FACIT- fatigue was maintained through Week 52.
Blandt patienter, der forblev på den apremilast-behandling de blev randomiseret til ved studiestart, blev DAS28(CRP)-score og PsARC-respons opretholdt til og med uge 52.
Among patients who remained on the apremilast treatment to which they were randomized at study start, DAS28(CRP) score and PsARC response were maintained through Week 52.
Blandt patienter, der forblev på den apremilast-behandling de blev randomiseret til ved studiestart, blev disse forbedringer opretholdt til og med uge 52.
Among patients who remained on the apremilast treatment to which they were randomized at study start, these improvements were maintained through Week 52.
Blandt patienter, der indledningsvist blev randomiseret til behandling med apremilast 30 mg to gange dagligt blev ACR 20/50/70-responsraterne opretholdt til og med uge 52 i de samlede studier PALACE 1, PALACE 2 og PALACE 3 (figur 1).
Among patients who were initially randomized to apremilast 30 mg twice daily treatment, ACR 20/50/70 response rates were maintained through Week 52 in the pooled Studies PALACE 1, PALACE 2 and PALACE 3 (Figure 1).
Blandt patienter, som fik afbrudt behandlingen med Humira ved uge 12 i HS-studie I og II, var HiSCR-raten 12 uger efter genoptagelse af behandling med Humira 40 mg ugentlig tilbage på lignende niveauer, som der blev observeret før behandlingsafbrydelse (56,0 %).
Among patients whose Humira treatment was withdrawn at Week 12 in Studies HS-I and HS-II, the HiSCR rate 12 weeks after re-introduction of Humira 40 mg weekly returned to levels similar to that observed before withdrawal (56.0 %).
Blandt patienter, som fortsatte behandling ud over 52 uger (i gennemsnit 96 uger), havde 81% af de 243 entecavir-behandlede og 39% af de 164 lamivudin-behandlede patienter HBV-DNA
At end of dosing, among patients who continued treatment beyond 52 weeks (median of 96 weeks), 81% of 243 entecavir-treated and 39% of 164 lamivudine-treated patients had HBV DNA
Blandt patienter, som gennemførte studiets 24 måneders behandling, var ikke-progessionsraterne henholdsvis 78 %, 70 % og 62 %.
Among patients who completed a full 24 months of therapy in the study, the non-progression rates were 78%, 70%, and 61%, respectively.
Blandt patienter, som var minimum delvise respondere ved uge 12, og som fik løbende ugentlig Humira-behandling, var HiSCR-raten 64,3% ved uge 48.
Among patients who were at least partial responders at Week 12, and who received continuous weekly Humira therapy, the HiSCR rate at Week 48 was 64.3%.
Blandt patienterne i SBR-armen, som opretholdt deres baseline-regime i 24 uger og derefter skiftede til FTC/RPV/TDF, havde 92 % (140/152) af patienterne hiv 1-rna < 50 kopier/ml efter 24 uger med FTC/RPV/TDF, hvilket var i overensstemmelse med resultaterne ved uge 24 for patienter, som skiftede til FTC/RPV/TDF ved baseline.
Among patients in the SBR arm who maintained their baseline regimen for 24 weeks and then switched to FTC/RPV/TDF, 92% (140/152) of patients had HIV-1 RNA < 50 copies/mL after 24 weeks of FTC/RPV/TDF, consistent with the Week 24 results for patients who switched to FTC/RPV/TDF at baseline.
Blandt patienterne med lymfon nåede 60 % af dem, der fik Mozobil, målantallet af stamceller inden for fire indsamlingsdage (89 ud af 150) sammenlignet med 20 % af de patienter, som fik placebo (29 ud af 148).
Among the patients with lymphoma, 60% of those receiving Mozobil achieved the target number of stems cells within four collection days (89 out of 150), compared with 20% of the patients receiving placebo (29 out of 148).
Blandt patienterne med multipelt myelom nåede 72 % af dem, der fik Mozobil, målantallet af stamceller (106 ud af 148) sammenlignet med 34 % af de patienter, som fik placebo (53 ud af 154).
Among the patients with multiple myeloma, 72% of those receiving Mozobil achieved the target number of stem cells (106 out of 148), compared with 34% of the patients receiving placebo (53 out of 154).
Blandt patienterne med tidligere relapse i T12/PR24-gruppen, som havde ikke- detekterbart HCV-RNA (HCV-RNA ikke påvist) i behandlingsuge 4 og 12, var SVR-raten 100% (24/24).
Among prior relapsers in the T12/PR24 treatment group who had undetectable HCV RNA (target not detected) at week 4 and 12 of treatment, the SVR rate was 100% (24/24).
Blandt patienterne, som fik dobbelt antitrombotisk behandling, fik 98,8 % clopidogrel, 0,9 % fik ticlopidin og 0,3 % fik prasugrel.
Among patients receiving dual anti-platelets therapy 98.8% received clopidogrel, 0.9 % received ticlopidine and 0.3 % received prasugrel.
Blandt personer med en følsomhedsscore for genotype ≤ 1 havde 76 % og 69 % hiv-1-rna
Among subjects with a genotypic sensitivity score of ≤ 1, 76% and 69% had HIV-1 RNA
Blandt prøverne fra mundslimhinde havde kun 1 prøve påviseligt talimogen laherparepvec-DNA under studiet, men prøven blev ikke testet positiv for forekomst af infektionsvirus.
Among samples of oral mucosa, only 1 sample had detectable talimogene laherparepvec DNA during the study, but the sample did not test positive for presence of infective virus.
Blandt studiedeltagerne med diarré var Mediantiden til første hændelse 2 dage (interval: 1-594 dage), og medianvarigheden pr. hændelse var 2 dage (interval: 1-910 dage).
Among patients with diarrhoea, the median time to first event was 2 days (range, 1 to 594 days) and the median duration of any grade of diarrhoea was 2 days (range, 1 to 910 days).
Blandt varianterne var 91 % af V36M, 98 % af T54A, 71 % af T54S, 78 % af V55A, 76 % af R155K, 92 % af A156S, 96 % af I/V170A, 77 % af
Among the variants, 91% of V36M, 98% of T54A, 71% of T54S, 78% of V55A, 76% of R155K, 92% of A156S, 96% of I/V170A, 77% of R155K+T54S and
Blastcellefri hypoplastisk eller aplastisk knoglemarv3
Blast free hypoplastic or aplastic bone marrow3
Blaster fuldstændig forsvundet fra kredsløb
Complete disappearance of circulating blasts
Blastfase tidligere behandlet med imatinib som minimum
Blast Phase With prior treatment of at least Imatinib
Blastkrise defineres som 30 % blaster i blod eller knoglemarv eller ekstramedullær sygdom ud over hepatosplenomegali.
Blast crisis is defined as blasts ≥ 30 % in blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Blastkrise er den mest fremskredne fase af denne sygdom,
Blast crisis is the most advanced stage of this disease.
Blastkrise og Ph+ ALL (startdosis
Blast crisis and Ph+
BLB 016 Bulebel Industrial Estate
BLB 016 Bulebel Industrial Estate Zejtun ZTN 3000
BLB16 Bulebel Industrial Estate, Zejtun ZTN 3000 Malta
BLB016 Bulebel Industrial Estate, Zejtun ZTN 3000 Malta
Blefaritis Vækst af øjenvipper Øget tåreflåd
Growth of eyelashes Lacrimation increased Ocular hyperaemia Dry eye
Bleg eller grålig hudfarve
Pale or greyish skin colour
Bleg hud
Paleness of the skin
Bleg hud
Skin paleness
Bleg hud, træthed, åndenød, mørkfarvet urin (hæmolytisk anæmi)
Pale skin, tiredness, breathlessness, dark-coloured urine (haemolytic anaemia)
bleg hud, træthed, åndenød, mørkfarvet urin (hæmolytisk anæmi, unormal nedbrydning af røde blodlegemer i blodårerne eller andre steder i kroppen)
pale skin, tiredness, breathlessness, dark-coloured urine (haemolytic anaemia, abnormal breakdown of red blood cells either in the blood vessels or elsewhere in the body)
Bleggul opløsning til injektion.
Pale yellow solution for injection.
Bleggul oral suspension.
Pale yellow oral suspension.
Bleggul til gul, oval, filmovertrukket tablet med delekærv og præget ” 1 0” på den ene side og ”M M” på den anden side.
Pale yellow to yellow, oval shaped film-coated tablet with breaking line and engravings “1 0” on one side and “M M” on the other side
Bleggul til gul, oval, filmovertrukket tablet med delekærv og præget ” 1-0” på den ene side og ”M M” på den anden side.
Pale yellow to yellow, oval shaped film-coated tablet with breaking line and engravings "1-0" on one side and "M M" on the other side
Bleggullig opløsning.
Colourless to pale yellow solution.
bleghed
pale skin
bleghed
paleness
bleghed
pallor
bleghed i huden, træthed eller blå mærker, da disse kan være tegn på blodsygdomme forårsaget af en ubalance i de forskellige typer blodceller som blodet er sammensat af.
pale skin, tiredness, or bruising, as these may indicate blood disorders caused by an imbalance in the different types of blood cells which make up blood,
bleghed i huden, træthed eller blå mærker, da disse kan være tegn på blodsygdomme forårsaget af en ubalance i de forskellige typer blodceller, som blodet er sammensat af.
Pale skin, tiredness, or bruising, as these may indicate blood disorders caused by an imbalance in the different types of blood cells which make up blood.
Bleghed, ansigtsrødme
Pallor, flushing
Bleghed, føle sig træt og stakåndet og have mørk urin (tegn på lavt antal røde blodceller).
Pale skin, feeling tired and breathlessness and having dark urine (signs of low levels of red blood cells).
bleghed, mangel på energi eller træthed
looking pale, feeling low in energy or tired
Bleghed, misfarvning af vener, hypotension
Pallor, vein discolouration, hypotension
Bleghed, rødme
Pallor, flushing
blepharospasmus, retinal blødning, uveitis
blepharospasm, retinal haemorrhage, uveitis.
Bleudslæt
Diaper rash
Blev i originalt behandlings-regime (n=97) n/N (%)
Stayed on original treatment regimen (N=97) n/N (%)
blevet undersøgt.
inhibitors:
BLIKDÅSE OG BLYBEHOLDER
TIN CAN AND LEAD POT
Blinatumomab er en bispecific T-cell engager antistofplatform, som binder specifikt til CD19, der udtrykkes på overfladen af celler med oprindelse i B-linjen og CD3, der udtrykkes på overfladen af T-celler.
Blinatumomab is a bispecific T-cell engager antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells.
Blinatumomab formidler dannelsen af en cytolytisk-synapse mellem T-cellen og tumorcellen og frigiver derved proteolytiske enzymer, der dræber både prolifererende og hvilende målceller.
Blinatumomab mediates the formation of a cytolytic synapse between the T-cell and the tumour cell, releasing proteolytic enzymes to kill both proliferating and resting target cells.
Blincyto anvendes til patienter, der er "Philadelphia-kromosom-negative" (Ph-).
It is used when the patients are ‘Philadelphia-chromosome-negative’ (Ph-).
Blincyto anvendes, når ALL er vendt tilbage eller patienten ikke har responderet på foregående behandling.
Blincyto is used when the ALL has come back or has not responded to previous treatment.
BLINCYTO blev undersøgt i et åbent fase II-multicenterstudie med en enkelt behandlingsarm med 189 patienter.
BLINCYTO was evaluated in an open-label, multicentre, single-arm phase II study of 189 patients.
Blincyto blev undersøgt i én hovedundersøgelse med 189 patienter med Ph- B-celle precursor ALL, hos hvem leukæmien var vendt tilbage, eller som ikke havde responderet på behandling.
Blincyto has been studied in one main study in 189 patients with Ph- B-cell precursor ALL whose leukaemia had come back or had not responded to treatment.
BLINCYTO bør ikke anvendes til børn og unge under 18 år.
BLINCYTO should not be used in children and adolescents below 18 years of age.
Blincyto er et kræftlægemiddel til behandling af voksne patienter med blodkræft af typen B-precursor akut lymfoblastisk leukæmi (ALL).
Blincyto is a cancer medicine used to treat adult patients with B-precursor acute lymphoblastic leukaemia (ALL), a type of blood cancer.
BLINCYTO er indiceret til behandling af voksne med Philadelphia-kromosom-negativ recidiveret eller refraktær B-prækursor akut lymfoblastisk leukæmi (ALL).
BLINCYTO is indicated for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).